Pacira Pharmaceuticals (NASDAQ:PCRX) traded on a positive note gaining 0.06 points or 0.15% to be valued at $39.83 per share. Intraday, the shares aggregated $3.84 million in upticks but saw an exodus of $7.75 million in downticks. The net money flow was calculated to be $(-3.92) million with the final up/down ratio coming in at 0.49. The share price has seen a change of -9.62% in value during the week. Block trade of up/down ratio of 0.19 was also registered with $0.97 million in upticks and $5.26 million in downticks. The net money flow for the block exchange was disappointing at $(-4.28) Million.
Pacira Pharmaceuticals, Inc. has lost 12.41% in the last five trading days and dropped 11.67% in the last 4 weeks. Pacira Pharmaceuticals, Inc. has dropped 19.28% during the last 3-month period . Year-to-Date the stock performance stands at -49.73%.
Currently the company Insiders own 6.9% of Pacira Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.36% . During last six month period, the net percent change held by insiders has seen a change of -17.47%. . On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Pacira Pharmaceuticals, Inc., Brege Laura had sold 1,000 shares worth of $46,950 in a transaction dated June 6, 2016. In this transaction, 1,000 shares were sold at $46.95 per share.
Pacira Pharmaceuticals (NASDAQ:PCRX) witnessed a decline in the market cap on Friday as its shares dropped 2.94% or 1.17 points. After the session commenced at $39.68, the stock reached the higher end at $40.24 while it hit a low of $38.42. With the volume soaring to 1,186,979 shares, the last trade was called at $38.6. The company has a 52-week high of $80.25. The company has a market cap of $1,435 million and there are 37,167,255 shares in outstanding. The 52-week low of the share price is $35.78.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.